Answers are grounded in this paper and cite their sources.
Carnosine (β-alanyl-L-histidine) is an endogenous dipeptide known for its anti-inflammatory and antioxidant effects, making it a promising agent for neurodegenerative diseases like Alzheimer’s disease (AD). Carnosine has shown protective effects against amyloid beta (Aβ)-induced oxidative stress and inflammation in murine microglial cells, yet its full immunomodulatory impact on these cells, particularly in terms of transcriptional regulation and cytokine interplay, remains underexplored. This study examined carnosine’s effects on immune response markers in BV-2 cells exposed to Aβ oligomers. Specifically, gene expression changes in anti-inflammatory mediators (CXCL2 and IL-10) and phagocytic markers (CD11b, CD68, TNFα, IL-1β) were assessed. Notably, carnosine increased CXCL2 and IL-10 expression, promoting an anti-inflammatory response and enhancing microglial phagocytosis. Additionally, carnosine restored CX3CR1 expression, a receptor implicated in Aβ-stimulated murine macrophages, and upregulated TGF-β1 and its receptor, supporting its neuroprotective role. These results underscore carnosine’s potential to modulate immune responses, enhance microglial activity, and provide neuroprotection in Aβ-induced conditions. The findings highlight carnosine’s therapeutic promise for AD treatment, offering a pathway for future research on its use in neurodegenerative disease interventions. • Carnosine increases IL-10 and CXCL2, reducing inflammation in microglial cells. • It restores CD11b and CD68, enhancing microglial phagocytic activity. • Carnosine upregulates TGF-β1 and TGFβR, supporting anti-inflammatory pathways. • It rescues CX3CR1 expression, aiding neuron-microglia communication in AD. • Carnosine shows promise as a therapeutic agent for Alzheimer's neuroprotection.
No takes yet. Share an insight, caveat, or question.
Rivi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: